Article Text

Download PDFPDF

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synovium
  1. C A Wijbrandts1,
  2. M G W Dijkgraaf2,
  3. M C Kraan1,
  4. M Vinkenoog1,
  5. T J Smeets1,
  6. H Dinant1,3,
  7. K Vos1,3,
  8. W F Lems4,5,
  9. G J Wolbink1,5,
  10. D Sijpkens1,
  11. B A C Dijkmans3,4,5,
  12. P P Tak1
  1. 1
    Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
  2. 2
    Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
  3. 3
    Jan van Breemen Institute, Amsterdam, The Netherlands
  4. 4
    Department of Rheumatology, Slotervaart Hospital, Amsterdam, The Netherlands
  5. 5
    VU Medical Center, Amsterdam, The Netherlands
  1. Professor P P Tak, Division of Clinical Immunology and Rheumatology, F4-218, Academic Medical Center/University of Amsterdam, Meibergdreef 9 1105 AZ Amsterdam, The Netherlands; P.P.Tak{at}amc.uva.nl

Footnotes

  • Funding: This study was funded by a Health Care Efficiency Research Programme grant from The Netherlands Organization for Health Research and Development (ZonMw) in assignment of The Netherlands Organization for Scientific Research (NWO) (grant number 945-02-029), the Dutch Arthritis Association and the European Community’s FP6 funding (Autocure).

  • Competing interests: PPT has served as a consultant for Abbott, Amgen, Centocor and Wyeth.

  • Ethics approval: The Medical Ethics Committee of the Academic Medical Center, University of Amsterdam approved the protocol. All patients gave written informed consent.

  • This publication reflects only the authors’ views. The European Community is not liable for any use that may be made of the information herein.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding: This study was funded by a Health Care Efficiency Research Programme grant from The Netherlands Organization for Health Research and Development (ZonMw) in assignment of The Netherlands Organization for Scientific Research (NWO) (grant number 945-02-029), the Dutch Arthritis Association and the European Community’s FP6 funding (Autocure).

  • Competing interests: PPT has served as a consultant for Abbott, Amgen, Centocor and Wyeth.

  • Ethics approval: The Medical Ethics Committee of the Academic Medical Center, University of Amsterdam approved the protocol. All patients gave written informed consent.

  • This publication reflects only the authors’ views. The European Community is not liable for any use that may be made of the information herein.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.